Recruiting
Biliary neoplasm
RecruitingStudy of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer
Registered drugNo placebo
Study of MP0317 with durvalumab, gemcitabine and cisplatin combination therapy as first-line treatment for patients with advanced biliary tract cancer
Registered drugNo placebo
- Disease:Biliary neoplasm
- Substances:CisplatinDurvalumab+2
Countries:
France
France- Participants:18–64 years · 65+ years
- Substances:Cisplatin
